Sarsia is an early-stage venture capital firm. We invest in a greener and healthier future.
Reliability is at the core of what we doVisit page
Background in science, experience from industry
Sarsia strenght lies in our differences; people with diverse backgrounds, knowledge and experience giving different perspectives.Visit page
- Visit page
Our focus is on unmet medical needs. Where competence and capital are decisive when turning a laboratory result into an effective treatment for the patient.
- Visit page
Technology, Energy and Sustainability
We search for technologies and founders capable of accelerating the green transition and of building sustainable companies for the future.
A talent for value creation begins with the will to dare the unknown
Theories, hypotheses and research are rooted in ambition. Clear goals, systematic hard work and dedication create results. Sarsia focus on technologies that can improve the quality of life, society and reduce negative impact on nature. Sarsia creates value by linking good solutions and science with competent capital. We thrive on change, and dare to take risks to create value. This has made us one of the best performing VC firms in the Nordic countries.
- 18Years since startup
- 1300mNOK (3 funds)
- 12600mNOK Portfolio IPEV Value
1417 companies screened
28 portfolio companies
Top performance among Norwegian Early Stage Venture funds
Two of the most valuable early stage venture backed companies in Norway.
It’s all about moving the planet forward
We are motivated by making a difference. By contributing to the development of technologies that have the potential to solve important challenges. That doesn’t always mean the easiest road to our goals. And achieving them requires both eagerness and endurance.
Fri Feb 16 2024
Sarsia is proud sponsor of WILD - Women in Life Science Norway
Sarsia Management is proud to announce that we are among the first sponsors of the newly established…Read full article
Wed Jan 24 2024
Arxx merges with Oxitope and raises EUR 75 million in a Series A
Arxx Therapeutics and Oxitope Pharma today announced their merger to form Calluna Pharma Inc. The n…Read full article
Wed Oct 04 2023
Pluvia Biotech appoints Willem van Weperen as new CEO
Pluvia Biotech announces the appointment of Willem van Weperen as its new Chief Executive Officer (C…Read full article